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Crohn's disease patients on long-term 6-mereaptopurine 
therapy (more than 4 months) were evaluated for activity 
of peripheral blood natural killer cells. Natural killer-cell 
cytolytic activity against K-562 tumor-cell targets was 
examined, as was natural killer-cell suppression of lym- 
phoblastoid B-ceU antibody production. In addition, 
these patients were studied for their ability to generate 
antitetanus-specific IgG antibody-producing lymphoblas- 
toid B cells following in vivo booster immunization. 
Crohn's disease patients on 6-mercaptopurine therapy 
had significant reductions in peripheral blood natural 
killer-cell activity against K-562 targets compared to 
normals, disease controls, and Crohn's disease patients 
not on 6-mercaptopurine. Natural killer-cell suppression 
of lymphoblastoid B-cell antibody production was like- 
wise decreased in 6-mercaptopurine-treated patients 
compared to normal controls. In contrast, the in vivo 
generated lymphoblastoid B-cell antibody responses of 
Crohn's disease patients on 6-mercaptopurine therapy 
were not decreased compared to normal, while Crohn's 
disease patients not on 6-mercaptopurine therapy had 
significantly impaired IgG antitetanus antibody respons- 
es. These findings suggest that 6-mercaptopurine therapy 
in Crohn's disease affects several lymphoid subpopula- 
tions, resulting in a decreased natural killer-cell cytotoxic 
activity against K-562 target cells and a decreased natur~ 
killer-cell ability to suppress lymphoblastoid B-cell anti- 
body production, as well as an improved humoral im- 
mune response following tetanus toxoid booster immuni- 
zation. 
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INTRODUCTION 
A role for immunological mechanisms in the patho- 
genesis of inflammatory bowel disease has been 
suspected for years, however, the nature of this 
involvement remains to be elucidated. The National 
Cooperative Crohn's Disease Study (1) showed no 
response to azathioprine therapy of 2 months' dura- 
tion. In contrast, Present et  al. (2) demonstrated 
that as many as 67% of patients with Crohn's 
disease received beneficial responses when placed 
on medical therapy employing 6-mercaptopurine (6- 
MP). They also noted that clinical responses may be 
delayed, requiring 3-6 months of therapy. Other 
clinical studies (3-5) have suggested that azathio- 
prine may be useful as a maintenance treatment in 
Crohn's disease. The mechanisms by which 6-MP 
effected a beneficial response in these studies were 
unknown. 
Previous studies by Campbell et al. (6, 7) showed 
that Crohn's disease and ulcerative colitis patients 
treated with azathioprine, which is metabolized in 
vivo to 6-MP, had a decrease in killer-cell (K-cell) 
activity. Shih et al. (8) have demonstrated a pro- 
found decrease in the activity of both K cells and 
natural killer cells (NK cells) in the peripheral blood 
of multiple sclerosis patients treated with azathio- 
prine. More recently, Prince et al. (9) showed that 
renal transplant patients on long-term azathioprine 
therapy had similar decreases in K-ceU and NK-cell 
activity. 
In this study, we have examined NK-cell cyto- 
toxic activity in Crohn's disease patients on and off 
long-term 6-MP therapy to see if decreased activity 
occurs as in other patient groups. We have also 
evaluated another aspect of NK-cell activity, the 
ability to suppress lymphoblastoid B-cell (LB B- 
cell) antibody production (10), to see if it is likewise 
decreased. In addition, IgG antitetanus antibody 
(IgG-Tet)-producing LB B cells were tested in 6- 
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MP-treated and untreated Crohn's disease patients 
following in vivo booster immunization with tetanus 
toxoid. Our findings indicate that long-term 6-MP 
therapy in Crohn's disease decreases both NK-cell 
cytotoxic and NK-cell antibody suppression activi- 
ty. LB B-cell antibody production after tetanus 
immunization was improved, perhaps because of 
decreased NK-cell suppressor activity. 
M A T E R I A L S  A N D  M E T H O D S  
Control and Patient Populations 
Normal controls consisted of healthy normal vol- 
unteers, mostly students and employees at the 
UCLA Medical Center. Gastrointestinal disease 
controls consisted of outpatients attending the 
UCLA Gastroenterology Clinic with a variety of 
gastrointestinal inflammatory conditions: two idio- 
pathic chronic gastritis, two gastric ulcer, two 
esophagitis, one chronic pancreatitis, and one acute 
enteritis. Systemic lupus erythematosus inflamma- 
tory controls were recruited from the Rheumatol- 
ogy Clinic at Harbor-UCLA Medical Center. 
Table I. Patient Characteristics 
Crohn's 
Crohn's disease 
disease on 6-MP 
Number 25 20 
Age (mean years - SD) 34.8 -+ 11.4 34 +- 13.4 
Sex (male/female) 12/13 10/10 
Disease location 
Small bowel 5 (20%) 7 (35%) 
Colon 3 (12%) 2 (10%) 
Small bowel and colon 17 (68%) 11 (55%) 
Disease activity ~ 
0 14 (56%) 12 (60%) 
+ 9 (36%) 6 (30%) 
++ 2 (8%) 2 (10%) 
Prior surgery 
Small bowel 3 (12%) 2 (10%) 
Colon 2 (8%) 0 (0%) 
Small bowel and colon 8 (32%) 6 (30%) 
Medications 
Prednisone 9 (36%) 7 (35%) 
Azulfadine 5 (20%) 9 (45%) 
Prednisone and azulfadine 3 (12%) 0 (0%) 
Normals: Healthy volunteers at the UCLA Medical Center 
Disease controls: 2 chronic gastritis, 2 gastric ulcer, 1 acute 
enteritis, 1 esophagitis, 1 chronic pancreatitis 
SLE controls: 9 patients with minimal disease activity; 5/9 on 
corticosteroid therapy 
"0, no symptoms; +, mild symptoms not interfering with normal 
activities; + +,  severe symptoms which interfere with normal 
activities. 
Crohn's disease patients were recruited from 
among those attending the Gastroenterology Clinic 
at UCLA, from those patients referred by other 
physicians in Los Angeles, or from patients in Dr. 
Korelitz's practice in New York. Clinical character- 
istics of the patients are outlined in Table I. All 
patients on 6-MP therapy had been treated for more 
than 4 months. All patients receiving corticosteroid 
therapy were on stable every-morning dosages and 
had taken their medications prior to phlebotomy. 
For control of assay systems, blood from the 
New York subjects (3 normals, 3 Crohn's not on 6- 
MP, 12 Crohn's on 6-MP) was collected the same 
day, maintained at 4°C while being flown to Los 
Angeles and was simultaneously tested at UCLA. 
Other normals, disease controls, and Crohn's dis- 
ease patients were tested over a 15-month period at 
UCLA. 
All subjects had received previous tetanus toxoid 
immunizations, but none had been immunized in 
the previous 12 months. All procedures performed 
with the normals, disease controls, and patients 
were approved by the UCLA Human Subject Pro- 
tection Committee. 
Materials 
Purified tetanus toxoid was generously provided 
by Wyeth Laboratories (Marietta, PA). Rabbit anti- 
human IgG used in enzyme-linked immunosorbent 
assays (ELISA) was obtained from Sigma Labora- 
tories (St. Louis, MO) and microtiter plates used in 
ELISA tests were obtained from Cooke (Alexan- 
dria, VA). Alpha interferon was a gift of Hoffman- 
LaRoche and Genentech Inc. Pokeweed mitogen 
was obtained from Grand Island Biological Co. 
Immunization 
Normal individuals, disease controls, and pa- 
tients were given an intramuscular booster immuni- 
zation with absorbed tetanus-diphtheria toxoids 
(Lederle Laboratories). Blood samples were col- 
lected just before and 7 days after booster immuni- 
zation. 
Lymphocyte Preparation 
Human mononuclear leukocytes were prepared 
by Ficoll-Hypaque density centrifugation of hepa- 
rinized peripheral blood obtained from the various 
donors (11). Samples transported from New York 
Journal of Clinical Immunology, Vol. 5, No. 3, 1985 
206 BROGAN, HISERODT, OLIVER, STEVENS, KORELITZ, AND TARGAN 
were kept at 4°C for approximately 12 hr before 
separating and testing. Samples were warmed to 
37°C prior to Ficoll-Hypaque centrifugation. To 
control for effects of cold incubation on NK activity 
and LB B-cell antibody production, four normal 
specimens were separated while fresh and following 
overnight incubation at 4°C. NK cytotoxic activity 
at effector to target ratios of 25/1 in fresh (67 -- 27%) 
and incubated specimens (60 --- 30%) was not signif- 
icantly different (P > 0.2). IgG-Tet production by 
fresh (76 ×/+ 3.6 ng/culture) and cold incubated 
cells (62 ×/+ 4.3 ng/culture) showed similar results 
(P > 0.2). 
Lymphocyte Cultures 
Triplicate cultures containing peripheral blood 
lymphocytes (1.5 million cells) were initiated in a 
final volume of 1.5 ml in round-bottom culture 
tubes. The cultures were incubated at 37°C with 5% 
CO2 for 3 days in a medium consisting of RPMI 
1640 buffered with NaHCO3 and supplemented with 
L-glutamine (I0 raM), gentamicin (0.05 mg/ml), and 
15% heat-inactivated fetal calf serum. 
Lymphoblastoid-Cell Suppression Cultures 
LB B-cell suppression cultures were performed 
similarly to lymphocyte cultures except that alpha 
interferon (100 U/ml) was added to stimulate NK 
cell-mediated suppression (10). 
ELISA Assays for Antibody Production 
The solid-phase quantitative ELISA tests for 
IgG-Tet were performed in microtiter plates as 
previously described (12), substituting alkaline 
phosphatase-coupled antibody for radioiodinated 
antibody in the developing antibody step. 
NK K-562 Cytotoxicity Assays 
Cytotoxicity tests were performed by 51Cr re- 
lease in standard 96-well V-shaped microplates 
(Cooke, Alexandria, VA), in a total volume of 200 
ixl. K-562 tumor-cell targets were labeled with 200 
ixCi of Na51Cr (New England Nuclear, Boston, 
MA) for 1 hr at 37°C and washed three times. Ten 
thousand target cells were used in each microtiter 
well. Effector-to-target ratios of 25/1 and I0/1 were 
used. After a 4- or 18-hr incubation period, 100 ixl of 
supernatant was collected and cytotoxicity was 
estimated from the released radioactivity according 
to the formula: [(test release-spontaneous re- 
lease)/(80% of total label-spontaneous re- 
lease)] x 100. 
Statistical Analysis 
Results of IgG-Tet production are expressed as 
the geometric mean ×/+ standard deviation (SD). 
All other results are expressed as the arithmetic 
mean --- SD. The statistical significance of differ- 
ences between groups was established using the 
Mann-Whitney U test. The variability of the re- 
sponse was evaluated by chi-square analysis of 
values lying outside the normal mean --- 2 SD. 
R E S U L T S  
NK-CelI Activity Against K-562 Targets 
Lymphocytes from both New York Crohn's dis- 
ease patient groups and normal controls were tested 
simultaneously for their ability to mediate cytolysis 
of the standard NK target cell K-562 (Fig. I). Seven 
of 12 patients from the New York group had suffi- 
cient numbers of lymphocytes after separation to 
test for NK-cell cytotoxicity. NK-cell activity at 
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Fig. 1. NK K-562 cytotoxicity of normal controls, Crohn's 
disease patients not on 6-MP therapy (CD), and Crohn's patients 
on 6-MP therapy (CD & 6-MP). All blood specimens were 
obtained from Dr. Korelitz's practice in New York and all assays 
were performed simultaneously. Effector-to-target ratios, 25/I. 
Bars represent arithmetic means + 1 SE. 
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effector-to-target ratios of 25/1 was not significantly 
different (P > 0.2) in normals (N = 3; 62 -+ 6.2% 
cytotoxicity) and Crohn's patients not on 6-MP (N 
= 3; 60.3 +- 7.4% cytotoxicity). Significant reduc- 
tions (P < 0.01) in the levels of detectable NK-cell 
activity were observed in patients receiving 6-MP 
therapy (N = 7; 19.9 - 12.6% cytotoxicity). These 
observations were extended during subsequent test- 
ing over a 15-month period at UCLA, using effec- 
tor-to-target ratios of 25/1 in a standard 51Cr release 
assay (Fig. 2). Normals (N = 32; 33 - 13.7% 
cytotoxicity) and gastrointestinal disease controls 
(N = 5; 33 -+ 21% cytotoxicity) were not significant- 
ly different (P > 0.2). Crohn's disease patients not 
on 6-MP (N = 22; 25.5 +- 15% cytotoxicity) had 
slightly decreased NK activity compared to nor- 
mals (0.04 < P < 0.05) but not compared to disease 
controls (P > 0.2). More impressive were the 
decreases (P < 0.01) in NK-cell activity (N = 10; 
10.7 --- 10% cytotoxicity) in patients on 6-MP thera- 
py compared to normals and Crohn's disease pa- 
tients not on 6-MP. Effector-to-target ratios of 10/I 
showed similar results (data not shown). There was 
little correlation between NK-cell activity and corti- 
costeroid dosage (Fig. 3), with r = 0.15 (P > 0.2) for 
Crohn's patients both on and off 6-MP therapy. 
NK-Cetl Suppression of Antibody Production 
To determine whether the subsets of  NK cells 
which are capable of suppressing LB B-ceU anti- 
body production in vitro (10) were also affected by 
6-MP therapy, simultaneous LB B cell-containing 
cultures were performed with the addition of inter- 
feron, a modulator which stimulates NK-cell sup- 
pression of antibody production. The results of 
these experiments are shown in Fig. 4. Normal 
lymphocytes (N = 7) cultured with interferon pro- 
duced significantly less IgG-Tet antibody (34.8 ×/+ 
1.34 ng/culture) than control cultures without inter- 
feron (65.4 ×/+ 1.34 rig/culture; P < 0.01). In 
similar experiments performed on lymphocytes iso- 
lated from patients on long-term 6-MP therapy (N = 
10), there was an absence of suppression of IgG-Tet 
production (P > 0.2) in cultures with interferon 
(69.4 ×/+ 3.2 ng/culture) in comparison to simulta- 
neous cultures without interferon (87.4 ×/+ 3.3 
ng/culture). 
LB B-Cell Generation 
Normal individuals, gastrointestinal disease con- 
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Fig. 2. NK K-562 cytotoxic activity of normal controls, gastrointestinal disease 
controls (GID), Crohn's disease patients not on 6-MP therapy (CD), and Crohn's 
patients on 6-MP therapy (CD & 6-MP). Assays were performed on Los Angeles 
patients over a 15-month period at UCLA. Effector-to-target ratios, 25/1, Bars 
represent arithmetic means + 1 SE. 
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Fig. 3. NK-cell cytotoxic activity against K-562 targets versus prednisone dosage. Dots represent data 
points of individual patients. 
controls, and Crohn's disease patients were booster 
immunized with tetanus toxoid. All normal individ- 
uals (N = 59) responded to the immunization with 
the production of antitetanus LB B-cell activity 7 
days after immunization (Fig. 5). There was no 
apparent difference in IgG-Tet production in the 
three normal specimens maintained at 4°C while 
being flown from New York to Los Angeles (data 
not shown). Normal values ranged from 44 to 325 
ng/culture, with a geometric mean of 110 ×/+ 1.6 
ng/culture. Gastrointestinal disease controls (N = 
7) responded to immunization, producing 92.8 ×/+ 
3.2 ng/culture, a value not significantly different 
from normal (P > 0.2). Systemic lupus erythemato- 
sus inflammatory controls (N = 9) also responded 
to immunization, producing 86 ×/+ 2.6 ng/culture, 
again not significantly different from normal (P > 
0.1). In contrast, Crohn's patients not on 6-MP (N 
= 25) had a markedly decreased IgG-Tet LB B-cell 
response (32.2 ×/+ 12.1 rig/culture), significantly 
less than normal (P < 0.002). Additional evaluation 
of the data revealed a wide variability of response in 
Crohn's patients not on 6-MP, with a range extend- 
ing from 0 to 3200 ng/culture. Eighty-six percent of 
these patients were outside the normal mean -+ 2 
SD (X 2 = 53, P < 0.01). To assess the effects of 6- 
MP on the ability of Crohn's disease patients to 
generate IgG-Tet LB B-cell responses, 16 patients 
on 6-MP therapy for more than 4 months were 
evaluated. The LB B-cell responses of these pa- 
tients were increased (81.4 x /+  2.8 ng/culture) 
compared to those of Crohn's patients not on 6-MP 
and were not significantly different from normal (P 
> 0.2). There was also a decrease in the variability 
of response, with only 36% of the patients lying 
outside the normal mean -+ 2 SD. The variability of 
response was still significantly increased compared 
to normal (X 2 = 13, P < 0.01) and resembled that of 
the gastrointestinal disease controls. There was no 
significant difference in the LB B-cell response of 
those patients receiving steroids and those not on 
steroid therapy (13). 
DISCUSSION 
Previous investigations of the immunosuppres- 
sive effects of azathioprine (6-9) have shown that 
its major effects following long-term in vivo therapy 
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Fig. 4. NK-cell suppression of LB B-cell IgG-Tet antibody production in normals 
and Crohn's disease patients on 6-MP therapy (CD & 6-MP). Shaded bars 
represent simultaneous cultures with interferon added to stimulate NK cell- 
mediated suppression. Bars represent geometric means + t geometric SD. 
are on NK- and K-cell cytotoxic lymphocytes. 
These cells are large granular lymphocytes which 
are quite similar phenotypically and, in fact, may be 
identical or overlapping populations which are cyto- 
toxic by different mechanisms (14). Initially Camp- 
bell et  al. (6, 7) demonstrated that inflammatory 
bowel disease patients treated with azathioprine 
had decreased K-cell activity as measured in an 
antibody-dependent cytotoxicity (ADCC) assay. 
Shih et al. (8) extended the in vivo evaluation of the 
effect of azathioprine on immune functions by pro- 
spectively studying a group of multiple sclerosis 
patients who had been treated with similar doses of 
this drug. The results from this study demonstrated 
a selective and profound decrease in the peripheral 
blood activity of K and NK cells. Other parameters 
tested, i.e., the T- and B-cell numbers and the 
phytohemagglutinin (PHA) and concanavalin A 
(Con A) proliferative responses, were unaffected. 
This reduced K- and NK-cell activity was due to a 
depletion of circulating cells and was not due to a 
decrease in cell function. A temporal delay in the 
loss of K- and NK-cell activity was observed, with 
an initial decline seen at 1 month after the initiation 
of therapy, followed by a nadir at 4-5 months. 
Interestingly, this time course was similar to that of 
clinical improvement seen in Crohn's disease pa- 
tients by Present et at. (2). More recently, Prince et 
al. (9) compared the immunosuppressive effects of 
long-term azathioprine versus prednisone therapy 
in renal transplant patients. They demonstrated that 
azathioprine, and not prednisone, suppressed NK 
and ADCC activity. 
The NK activity of peripheral blood lymphocytes 
in our Crohn's disease patients was slightly de- 
creased in comparison to that of normals but not 
that of gastrointestinal disease controls. Previous 
investigators have found both normal (15) and de- 
creased (16, 17) levels of peripheral blood NK-cell 
cytotoxic activity in inflammatory bowel disease. 
Differences in methodology, as well as differing 
levels of disease activity, may explain this variation 
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Fig. 5. LB B-cell IgG-Tet antibody production 7 days after 
immunization by normals, systemic lupus erythematosus inflam- 
matory controls (SLE), gastrointestinal disease controls (GID), 
Crohn's disease patients not on 6-MP (CD), and Crohn's disease 
patients on 6-MP therapy (CD + 6-MP). Bars represent geomet- 
ric means + 1 geometric SD. 
in NK-cell cytotoxic activity. Ginsberg et  al. (16) 
tested NK cytotoxicity following overnight culture 
of lymphocytes, which results in the activation of 
normal NK-ceU cytotoxicity. Our patients as well 
as those of James et  al. (15) had minimal disease 
activity in comparison to those in studies which 
demonstrated decreased NK cytotoxicity activity 
(16, 17). 
We have demonstrated that decreased NK-cell 
cytotoxic activity as well as decreased NK-cell 
suppression of LB B-cell antibody production oc- 
curs in the peripheral blood of Crohn's disease 
patients on long-term 6-MP therapy. These anti- 
body-suppressing cells in normals are stimulated by 
interferon, are subject to cold target competition by 
K-5~i2 cells, and express the Leu I l phenotype (10). 
They may represent a subset of NK cells. 
Although the NK activity against K-562 targets is 
normal or slightly decreased in Crohn's disease 
patients not on 6-MP, it is possible that a subset of 
NK cells directed against LB B cells is increased in 
Crohn's patients, contributing to their abnormal 
antibody responses to tetanus. A second possibility 
is that greater activity of NK cells is induced by 
immunization in Crohn's patients than in normals. 
These hypotheses are currently being pursued. 
There was little correlation between corticoste- 
roid dosage and NK cytotoxic activity. This con- 
firms the lack of corticosteroid effect on NK-cell 
cytotoxicity seen by Prince et  al. (9). 
The relationship of these findings to the clinical 
efficacy of 6-MP therapy is uncertain. Recent stud- 
ies, however, have demonstrated a role for K and 
NK cells in intestinal tissue. Animal experiments 
using functional and monoclonal analysis have 
shown the presence of large granular lymphocytes 
(NK and K cells) among the small intestine and 
colonic intraepithelial and Peyer's patch cells (I8- 
20). Reynolds et  al. have demonstrated that large 
granular lymphocytes injected into rats preferential- 
ly home to the intestines (18). Additional studies in 
our laboratory have demonstrated the presence of 
endogenous as well as interferon-activatable NK 
cells in normal intestine (21) and, more recently, 
have suggested that increased NK-cell cytotoxic 
activity may be seen in Crohn's disease intestine 
(22). Britton et  al. (23) have previously shown an 
increase in K cells in the mesenteric lymph nodes of 
Crohn's disease patients. Shorter et  al. (24) have 
isolated mononuclear cells from colonic mucosa of 
inflammatory bowel disease patients which are cy- 
totoxic for autologous colonic epithelial cells, possi- 
bly by a K- or NK-cell mechanism. Further studies 
of NK cells at the intestinal level in Crohn's pa- 
tients are required to determine the existence of 
NK-cell cytotoxic or antibody suppression activity 
in this compartment and its relationship to the 
clinical efficacy of 6-MP therapy. 
In a previous study, we demonstrated that many 
Crohn's disease patients have defects in their hu- 
moral immune system in that they fail to generate 
normal levels of IgG-Tet antibody-producing LB B- 
cell activity following in v ivo immunization (13). In 
addition, these patients failed to show increases in 
serum levels of tetanus toxoid-specific IgG anti- 
body. The present study adds new findings to the 
abnormal LB B-cell responses to tetanus recently 
associated with Crohn's disease patients not on 6- 
MP therapy. 6-MP-treated Crohn's patients made a 
significant IgG-Tet LB B-cell response following 
immunization. In addition, the variability of the 
response was decreased, with fewer patients lying 
outside the normal range. This improved LB B-cell 
response to tetanus may be related to the decreased 
NK-cell suppressor activity seen in these patients. 
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These suppressor cells may represent a previously 
unrecognized lymphoid subpopulation which is sen- 
sitive to 6-MP therapy. Further prospective evalua- 
tions of these cells in inflammatory bowel disease 
patients will help to determine the sensitivity of 
these NK suppressor cells to 6-MP therapy as well 
as the relationship between improved humoral re- 
sponsiveness and clinical efficacy. 
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